Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis.
暂无分享,去创建一个
M. Boaz | S. Smetana | Z. Matas | M. Fainaru | M. Green | Z. Katzir | A. Biro
[1] F. J. Romero,et al. Lipid peroxidation products and antioxidants in human disease. , 1998, Environmental health perspectives.
[2] J. Díaz,et al. Reference intervals for four biochemistry analytes in plasma for evaluating oxidative stress and lipid peroxidation in human plasma. , 1998, Clinical chemistry.
[3] J. Nally. Cardiac disease in chronic uremia: investigation. , 1997, Advances in renal replacement therapy.
[4] S. Tam,et al. Regulation of Human Apolipoprotein A-I Gene Expression by Gramoxone* , 1997, The Journal of Biological Chemistry.
[5] F. T. Stevenson,et al. Determinants of albumin concentration in hemodialysis patients. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] J. Himmelfarb,et al. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. , 1997, Journal of the American Society of Nephrology : JASN.
[7] J. Raynes,et al. Alterations in serum lipids in lepromatous leprosy patients with and without ENL reactions and their relationship to acute phase proteins. , 1996, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.
[8] A. Favier,et al. Assessment of radical activity during the acute phase of myocardial infarction following fibrinolysis: utility of assaying plasma malondialdehyde. , 1995, Free radical biology & medicine.
[9] C. Loughrey,et al. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. , 1995, Clinical chemistry.
[10] D. Blake,et al. Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. , 1995, Kidney international.
[11] G. Assmann,et al. Association of Variables of Coagulation, Fibrinolysis and Acute-phase with Atherosclerosis in Coronary and Peripheral Arteries and those Arteries Supplying the Brain , 1995, Thrombosis and Haemostasis.
[12] M. Thomas,et al. Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E, and iron status. , 1994, Free radical biology & medicine.
[13] G. Bellomo,et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? , 1994, Kidney international.
[14] J. Daugirdas. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. , 1993, Journal of the American Society of Nephrology : JASN.
[15] M. Koch,et al. Morbidity and mortality due to hypertension in patients with renal failure. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] T. Zima,et al. Lipid peroxidation on dialysis membranes. , 1993, Biochemistry and molecular biology international.
[17] M. Toborek,et al. Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. , 1992, Metabolism: clinical and experimental.
[18] A. Hamsten,et al. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man , 1992, The Lancet.
[19] J. Salonen,et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis , 1992, The Lancet.
[20] D. Steinberg,et al. Role of oxidized low density lipoprotein in atherogenesis. , 1991, The Journal of clinical investigation.
[21] A. J. Valente,et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. , 1991, The Journal of clinical investigation.
[22] Haihua,et al. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. , 1991, The American journal of pathology.
[23] M. Territo,et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. , 1990, The Journal of clinical investigation.
[24] K. Kugiyama,et al. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins , 1990, Nature.
[25] A. Hamsten,et al. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[26] J L Witztum,et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. , 1989, The Journal of clinical investigation.
[27] M. Haberland,et al. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. , 1988, Science.
[28] D. Steinberg,et al. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[29] D. Steinberg,et al. Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[30] D. Morel,et al. Monocytes and Neutrophils Oxidize Low Density Lipoprotein Making It Cytotoxic , 1985, Journal of leukocyte biology.
[31] D. Morel,et al. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. , 1983, Journal of lipid research.
[32] D. Steinberg,et al. Enhanced Macrophage Degradation of Biologically Modified Low Density Lipoprotein , 1983, Arteriosclerosis.
[33] D. Steinberg,et al. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[34] A. Sniderman,et al. Low Density Lipoprotein: A METABOLIC PATHWAY FOR RETURN OF CHOLESTEROL TO THE SPLANCHNIC BED , 1978 .
[35] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[36] M. Aviram,et al. Increased uptake of LDL by oxidized macrophages is the result of an initial enhanced LDL receptor activity and of a further progressive oxidation of LDL. , 1997, Free radical biology & medicine.
[37] L. Colacicco,et al. Coenzyme Q10 levels, plasma lipids and peroxidation extent in renal failure and in hemodialytic patients. , 1994, Molecular aspects of medicine.
[38] P. Schuff-Werner,et al. Plasma lipids are not oxidized during hemodialysis. , 1994, Nephron.
[39] P. Parfrey. Cardiac and cerebrovascular disease in chronic uremia. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[40] H. Esterbauer,et al. Role of vitamin E in preventing the oxidation of low-density lipoprotein. , 1991, The American journal of clinical nutrition.
[41] R. von Baehr,et al. Changes of antioxidative homeostasis in patients on chronic haemodialysis. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[42] F. Turci,et al. Elevated serum levels of C-reactive protein in hemodialysis patients. , 1990, Nephron.
[43] R. Bird,et al. Comparative studies on different methods of malonaldehyde determination. , 1984, Methods in enzymology.